Finding ways to overcome cancer drug resistance using small molecules
Overcoming drug resistance using small molecule activators of protein phosphatase 2A
This study is looking at how some tiny molecules can help a protein fight against drug resistance in cancer, especially for people with non-small cell lung cancer, to find better ways to make current treatments work more effectively.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-10676204 on NIH RePORTER |
What this research studies
This research investigates how certain small molecules can activate a protein called protein phosphatase 2A to combat drug resistance in cancer treatments. It focuses on the role of cyclin D1 and its associated proteins in promoting cancer cell survival and proliferation. By understanding the mechanisms behind drug resistance, the research aims to identify new therapeutic strategies that could enhance the effectiveness of existing cancer treatments, particularly for patients with non-small cell lung cancer. The approach includes laboratory experiments to test the effects of these small molecules on cancer cell lines.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with non-small cell lung cancer who have experienced resistance to existing therapies.
Not a fit: Patients with cancers that do not involve cyclin D1 or those who have not undergone prior cancer treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that overcome current drug resistance, improving outcomes for patients.
How similar studies have performed: Previous research has shown promise in targeting cyclin-dependent kinases in cancer therapy, indicating that this approach could yield significant advancements.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Black, Jennifer D. — University of Nebraska Medical Center
- Study coordinator: Black, Jennifer D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.